Squarepoint
CERE

Squarepoint’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Squarepoint’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-288,200
Closed -$11.8M – 4844
2024
Q2 		$11.8M Buy
+288,200
New +$12M 0.02% 854

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Squarepoint's CERE Position: Q3 2024 in Review

Squarepoint sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 446,018 shares — an estimated $18.2M sold.

Squarepoint first reported a position in CERE in Q3 2021 and held it in 10 quarters. The position peaked at $18.2M in Q2 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Squarepoint reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Squarepoint sold 446,018 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $18.2M.
  • Squarepoint first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2021 and held it in 10 quarters.
  • Squarepoint's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $18.2M in Q2 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Squarepoint's 13F filing for Q3 2024, filed 14 Nov 2024.